Literature DB >> 22201900

The immunomodulating roles of glycoproteins in epithelial ovarian cancer.

Manish S Patankar1, Jennifer A A Gubbels, Mildred Felder, Joseph P Connor.   

Abstract

The complexity of the immune system demands an intricate defense mechanism by tumors. Ovarian and other tumors employ specific glycoproteins and the associated glycan sequences to modulate immune responses. Glycoproteins enable tumor cells that express or secrete these molecules to evade immune cell attack and induce the immune system to promote tumor growth. This review focuses first on the immune environment in ovarian cancer, and the mechanisms of activation and inhibition that immune cells undergo in order to either attack or ignore a target cell. Next we illustrate the immunomodulatory roles of ovarian cancer-associated glycans and glycoproteins in 1. preventing immune synapse formation, 2. serving as ligands of immune cell receptors, 3. scavenging cytokines and chemokines, and 4. participating in the formation of autoantibodies against the tumor. The importance of these immunomodulating strategies from the view points of understanding the tumor immunology of ovarian tumors, potential origin of such mechanisms, and specific strategies to circumvent the glycoconjugate-mediated suppression of immune responses is discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22201900      PMCID: PMC4326102          DOI: 10.2741/405

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  230 in total

Review 1.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

Review 2.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.

Authors:  Mark J Smyth; Gavin P Dunn; Robert D Schreiber
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

3.  Interleukin 2 is a lectin that associates its receptor with the T-cell receptor complex.

Authors:  J P Zanetta; C Alonso; J C Michalski
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

4.  Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.

Authors:  Beatrice W T Yin; Ann Dnistrian; Kenneth O Lloyd
Journal:  Int J Cancer       Date:  2002-04-10       Impact factor: 7.396

5.  Progesterone and implanting blastocysts regulate Muc1 expression in rabbit uterine epithelium.

Authors:  L H Hoffman; G E Olson; D D Carson; B S Chilton
Journal:  Endocrinology       Date:  1998-01       Impact factor: 4.736

Review 6.  Galectins and cancer.

Authors:  André Danguy; Isabelle Camby; Robert Kiss
Journal:  Biochim Biophys Acta       Date:  2002-09-19

7.  LacdiNAc-glycans constitute a parasite pattern for galectin-3-mediated immune recognition.

Authors:  Timo K van den Berg; Henk Honing; Niels Franke; Alexandra van Remoortere; Wietske E C M Schiphorst; Fu-Tong Liu; André M Deelder; Richard D Cummings; Cornelis H Hokke; Irma van Die
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

8.  Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization.

Authors:  M Yoshimura; Y Ihara; A Ohnishi; N Ijuhin; T Nishiura; Y Kanakura; Y Matsuzawa; N Taniguchi
Journal:  Cancer Res       Date:  1996-01-15       Impact factor: 12.701

9.  Identification and characterization of a UDP-GalNAc:GlcNAc beta-R beta 1-->4-N-acetylgalactosaminyltransferase from cercariae of the schistosome Trichobilharzia ocellata. Catalysis of a key step in the synthesis of N,N'-diacetyllactosediamino (lacdiNAc)-type glycans.

Authors:  A P Neeleman; W P van der Knaap; D H van den Eijnden
Journal:  Glycobiology       Date:  1994-10       Impact factor: 4.313

10.  Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.

Authors:  Jennifer A A Gubbels; Jennifer Belisle; Masanori Onda; Claudine Rancourt; Martine Migneault; Mitchell Ho; Tapan K Bera; Joseph Connor; Bangalore K Sathyanarayana; Byungkook Lee; Ira Pastan; Manish S Patankar
Journal:  Mol Cancer       Date:  2006-10-26       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.